MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical
company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced
that on Wednesday, February 13, 2019, the Company will report financial results for its fiscal 2019 first quarter ended December
31, 2018, before the market opens. Veru’s management will host a conference call that same day at 8 am Eastern Time to review
the Company’s performance and to answer questions.
Event Details
Interested investors may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to
be joined into the Veru Inc. call.
In addition, investors may access a replay of the conference call the same day beginning at approximately noon Eastern Time by
dialing 877-344-7529 for U.S. callers, or 412-317-0088 from outside the U.S., passcode 10128045. The replay will be available
for one week, after which, the recording will be available via the company’s website at https://verupharma.com/investors.
About Veru Inc.
Veru Inc. is an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care
and urology specialty pharmaceuticals. The Veru prostate cancer pipeline includes zuclomiphene citrate (also known as
VERU-944, cis-clomiphene) and VERU-111 (bisindole). Zuclomiphene citrate is an estrogen
receptor agonist being evaluated in a Phase 2 trial to treat hot flashes, a common side effect caused by hormone treatment for men
with advanced prostate cancer. VERU-111 is an oral, next-generation, first-in-class selective small molecule that targets and
disrupts alpha and beta subunits of microtubules in cells to treat metastatic prostate cancer patients whose disease is resistant
to both castration and novel androgen blocking agent (abiraterone or enzalutamide) therapies. VERU-111 is being evaluated in
men with metastatic refractory prostate cancer in an open label phase 1b/2 clinical trial.
Veru is also advancing new drug formulations in its specialty pharmaceutical pipeline addressing unmet medical needs in urology.
The clinical trial of the Company’s proprietary Tadalafil and Finasteride Combination tablet (TADFIN™ tablet) met FDA requirements
for bioavailability and bioequivalence for the co-administration of tadalafil 5mg and finasteride 5mg dosed daily for benign
prostatic hyperplasia (BPH). Tadalafil (CIALIS®) is currently approved for treatment of BPH and erectile dysfunction and
finasteride (PROSCAR® and PROPECIA®) is currently approved for treatment BPH and male pattern hair loss. The
co-administration of tadalafil and finasteride has been shown to be more effective for the treatment of BPH than either drug alone.
The Company anticipates submitting an NDA for its TADFIN™ tablet under the 505(b)(2) regulatory pathway in the second half of
calendar year 2019. Veru is also developing Tamsulosin DRS granules and Tamsulosin XR capsules which are formulations of
tamsulosin, the active ingredient in FLOMAX®, which Veru has designed to avoid the “food effect” inherent in currently
marketed formulations of the drug, allowing for potentially safer administration and improved patient compliance.
Veru’s Female Health Company Division markets the FC2 Female Condom / FC2 Internal Condom®, an FDA-approved product
for the dual prevention of unwanted pregnancy and sexually transmitted infections, and the PREBOOST® medicated
individual wipe for the prevention of premature ejaculation. The FC2 Female Condom / FC2 Internal Condom is marketed
commercially and in the public health sector both in the U.S. and globally. FC2 is available by prescription in the U.S.
including through the virtual doctor smartphone app “HeyDoctor” at www.fc2.us.com. For PREBOOST®, Veru has a co-promotion
and distribution agreement with Timm Medical Technologies, Inc., a specialty urology sales organization, and the Company also
entered into a U.S. distributor agreement with a premier and fast-growing men’s health and telemedicine company that discreetly
sells men’s health products via the internet. To learn more about these products please visit www.verupharma.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release that are not historical facts are "forward-looking statements" as that term is defined in the
Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements relating to the
regulatory pathway to secure FDA approval of the Company's drug candidates and the anticipated timeframe for clinical studies,
clinical study results and FDA submissions. Any forward-looking statements in this release are based upon the Company's current
plans and strategies and reflect the Company's current assessment of the risks and uncertainties related to its business and are
made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this
release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to
known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the
assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors
that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not
limited to, the following: risks related to the development of the Company's product portfolio, including clinical trials,
regulatory approvals and time and cost to bring to market; potential delays in the timing of and results from clinical trials and
studies and the risk that such results will not support marketing approval and commercialization; potential delays in the timing of
any submission to the FDA and regulatory approval of products under development; risks relating to the ability of the Company to
obtain sufficient financing on acceptable terms when needed to fund development and operations; product demand and market
acceptance; competition in the Company's markets and the risk of new or existing competitors with greater resources and
capabilities and new competitive product introductions; price erosion, both from competing products and increased government
pricing pressures; manufacturing and quality control problems; compliance and regulatory matters, including costs and delays
resulting from extensive governmental regulation, and effects of healthcare insurance and regulation, including reductions in
reimbursement and coverage or reclassification of products; some of the Company's products are in development and the Company may
fail to successfully commercialize such products; risks related to intellectual property, including the uncertainty of obtaining
patents, the effectiveness of the patents or other intellectual property protections and ability to enforce them against third
parties, the uncertainty regarding patent coverages, the possibility of infringing a third party’s patents or other intellectual
property rights, and licensing risks; government contracting risks, including the appropriations process and funding priorities,
potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government
tenders and contracts may be subject to cancellation, delay, restructuring or substantial delayed payments; a governmental tender
award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units,
and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum
tender amount or award; penalties and/or debarment for failure to satisfy tender awards; the Company's reliance on its
international partners and on the level of spending by country governments, global donors and other public health organizations in
the global public sector; risks related to concentration of accounts receivable with our largest customers and the collection of
those receivables; the economic and business environment and the impact of government pressures; risks involved in doing business
on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade
barriers; the Company's production capacity, efficiency and supply constraints and interruptions, including due to labor unrest or
strikes; risks related to the costs and other effects of litigation, including product liability claims; the Company's ability to
identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company's ability to
successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases,
shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended
September 30, 2018. These documents are available on the "SEC Filings" section of our website at www.verupharma.com/investors.
Contact:
Kevin Gilbert 786-322-2213
